- Home
- CLMT vs MNKD Comparison
CLMT vs MNKD Comparison
Compare CLMT & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLMT | MNKD |
|---|---|---|
| Founded | 1916 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2024 | 2004 |
Fundamental Metrics
Financial Performance| Metric | CLMT | MNKD |
|---|---|---|
| Price | $33.59 | $2.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $28.65 | $8.64 |
| AVG Volume (30 Days) | 1.3M | ★ 4.8M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.39 | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | ★ $4,137,100,000.00 | $348,966,000.00 |
| Revenue This Year | $3.94 | $35.81 |
| Revenue Next Year | $1.07 | $11.89 |
| P/E Ratio | ★ N/A | $128.50 |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $8.88 | $2.23 |
| 52 Week High | $36.94 | $6.51 |
Technical Indicators
Market Signals| Indicator | CLMT | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 59.59 | 36.04 |
| Support Level | $17.58 | $2.52 |
| Resistance Level | $36.94 | $6.18 |
| Average True Range (ATR) | 1.79 | 0.13 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 64.90 | 74.44 |
Price Performance
Historical ComparisonAbout CLMT Calumet Specialty Products Partners L.P.
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets. Its segments include: Specialty Products and Solutions; Montana/Renewables; Performance Brands; and Corporate. The company generates maximum revenue from Fuels, asphalt and other by-products.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.